Allstocks.com's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » CBAI - Record Revenues » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    
Message:

HTML is not enabled.
UBB Code™ is enabled.

 

Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?
Options


Disable Graemlins in this post.


 


T O P I C     R E V I E W
Persia  - posted
LOS ANGELES, April 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --

Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company ( http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today revenues for 2006 topped $3.89 million, up 71 percent compared to revenues of $2.28 million in 2005.

The Company posted a gross profit of $703,933 in 2006, up 37 percent compared to $513,340 in the previous year. The net loss decreased to $(5.69) million compared to $(6.13) million in 2005, and diluted loss per share decreased 21 percent to $(0.14) in 2006. The loss from operations decreased significantly in 2006, as the company recorded a $2. 1 million interest expense, more than 35% of the loss.

The financials do not reflect the recent acquisition of CorCell, Philadelphia, Pa., the nation's fourth largest umbilical cord blood stem cell company.

Revenues for the fourth quarter of 2006 totaled $1.31 million, the third straight quarter topping the one million dollar plateau and the best quarter in the Company's history.

"The results we are posting, we believe, will be recognized as a significant achievement by both the financial markets and by investors," said Matthew Schissler, CEO. "We are extremely encouraged by our 2006 financial results."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at http://www.corcell.com . For investor information, visit http://www.cordblood-america.com .
 
Persia  - posted
LOS ANGELES, May 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that CEO Matthew Schissler on the National Business Radio Show "Your Monies Worth" said the Company is moving closer to eliminating its registered debt.

"Debt helped this Company grow and grow quickly," Mr. Schissler told the national radio and Internet audience. "But we believe our stock price is languishing because of the debt. The majority of the registered debt has been absorbed by the market in recent weeks, putting pressure on our stock. We feel we are close to eliminating the registered debt altogether." Schissler commented further, "Clearing the debt along with positive growth have been the two top priorities of CBAI in 2007. So far, we believe we are executing well on this plan."

Cord Blood America's CEO said progress at the Company has been strong, with a 71 percent growth in revenues and a subsequent reduction in losses from 2005 to 2006.

"The Company, going forward, is focused on strategic accretive acquisitions, intelligent organic growth and becoming the nation's first sustainable cash flow positive stem cell storage company," Mr. Schissler told the show's host, Mick Bazsuly.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
 
Persia  - posted
Cord Blood America First Quarter Revenues Total $1.7 Million, Up 208 Percent
5/22/2007

LOS ANGELES, May 22, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, reported today that revenues for the first quarter ended March 31, 2007, totaled $1.698 million, a new record quarter for the Company and up 208 percent compared to revenues totaling $551,060 in the same quarter in 2006.

The Company reported gross profit of $599,255 in the first quarter of 2007 compared to gross profit of $25,852 in the same period in 2006. Cord Blood America narrowed its loss to $(1.1) million for the period ended March 31, 2007, compared to a loss of $(1.8) million in the first quarter of 2006, a 39% reduction.

"Two key performance indicators are especially telling. The Company recorded a loss from operations of $(520,035), down 145 percent from $(1.3) million from the first quarter of 2006. The Company's loss per share went down to $(0.02) compared to $(0.04) for same period last year," said Matthew Schissler, Chairman and CEO. "These are the numbers we sought and we will continue to improve them in upcoming quarters."

The Company reported a significant reduction in administrative and selling expenses in the first quarter, as cost cutting measures implemented in 2006, including labor and marketing cuts, and decreases in fees to directors, are starting to have an impact.

"The robust growth for this quarter shows that the business model we have established is working well," said Mr. Schissler. "We will continue to seek accretive acquisitions and growth that make sense but do not dilute shareholders. Strengthening our balance sheet is a primary objective of our Company."

This is the fourth straight quarter that revenues topped one million dollars. Revenues from the Company's acquisition of CorCell Inc., Philadelphia, Pa., played a key role in the growth of Cord Blood America.
 
Guy Tough  - posted
Nice news, may bounce ?


Cord Blood America Six Month Revenues Total $4.04 Million, Up 221 Percent
Wednesday August 15, 5:00 am ET


LOS ANGELES, Aug. 15 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company ( http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families in all 50 states and internationally, reported today that revenues for the second quarter ended June 30, 2007, totaled $2.346 million, a record quarter for the Company, up 194 percent compared to revenues totaling $797,907 in the second quarter of 2006.


Revenues for the first six months of 2007 totaled $4.04 million, up 221 percent compared to revenues of $1.26 million in the first half of 2006. Revenues for the Company have now topped one million dollars for five consecutive quarters.

The Company reported a gross profit of $796,761 in the second quarter of 2007 compared to a gross profit of $125,255 in the same period in 2006. Gross profit for the first six months of 2007 totaled $1.396 million, up 1,439 percent compared to a gross profit of $96,641 in the first half of 2006. Cord Blood America announced a net loss of $(1.76 million), or $0.02 a share, in the second quarter of 2007 and a net loss for the first half of 2007 of $(3 million), or $0.04 a share compared to a loss of $0.07 per share for the same period in 2006.

"There were many positives in the first half of 2007 and a most important key indicator of this is gross profit, which increased from 21% of revenues to 34%. Economies of scale, especially for the Company's Cord Blood division, started to positively impact the Company's financial results," said Matthew Schissler, CEO, Cord Blood America. "We intend to remain focused on our successful strategy of strategic, organic growth, accretive acquisitions and reducing overhead in the upcoming reporting periods."

"Strong growth for the quarter, combined with a significant decrease in marketing costs, shows that the strategies we are pursuing are promoting excellent results," said Mr. Schissler. "We are very pleased to present these financial achievements to our shareholders."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.


CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick*eandecommunications.com


--------------------------------------------------------------------------------
Source: Cord Blood America, Inc.
 
Guy Tough  - posted
daily

 -
 
Guy Tough  - posted
oops
 
Guy Tough  - posted
2 year weekly:

 -
 
Guy Tough  - posted
Jumped 32% today---

[Big Grin]

 -
 
Guy Tough  - posted
Now this appears to be starting a nice new uptrend. .053 x .054 and volume is picking up.
Just moved back up above 5 MA again today after a
10 MA bounce...

 -
 
Guy Tough  - posted
Cord Blood America CEO Matthew Schissler in Internet Interview Says Investors Should Focus on Stem Cell Sector

LOS ANGELES, Aug. 29 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), is the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families in all 50 states and internationally. Matthew Schissler, CEO, is featured in an exclusive interview with Jason Buchen posted at http://www.EquityGroups.com .

The link to the interview is at
http://equitygroups.com/audioint/cbai/cbai24aug.wmv .

In the interview, Mr. Schissler says investors should be increasingly interested in the stem cell sector because many more afflictions will be treated, and cured, by stem cells within the next two to five years. 'We are the fastest growing stem cell company that we know about, and are highly undervalued,' the CEO of Cord Blood America said. 'We are positioning our Company to be in control of the inventory, which is crucial to significant corporate growth.'

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as 'anticipate,' 'believe,' 'expect,' 'future,' 'intend,' 'plan,' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick*eandecommunications.com

SOURCE Cord Blood America, Inc.


Source: PR Newswire (August 29, 2007 - 4:00 AM EST)

News by QuoteMedia
www.quotemedia.com
 



Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share